Hepetra

Hepetra is a human hepatitis B immunoglobulin (HBIG) provided as an intravenous solution; the exact strength is not disclosed. It contains purified anti‑HBs antibodies derived from human plasma and is marketed in the European Union as a prescription‑only product. The preparation supplies passive immunity by delivering antibodies that neutralize hepatitis B virus and is used in protocols for newborns, transplant recipients, and persons with occupational exposure.

Hepetra is indicated for several prophylactic situations where hepatitis B virus exposure risk is high.

- Post‑exposure prophylaxis for individuals who have had a known or suspected exposure to hepatitis B virus. - Prevention of hepatitis B infection in newborn infants born to mothers who are HBsAg‑positive. - Prophylaxis in patients undergoing liver transplantation to prevent de novo infection. - Immunoprophylaxis for patients receiving immunosuppressive therapy or chemotherapy that may increase susceptibility to hepatitis B. - Use in occupational settings for healthcare workers after accidental needle‑stick injuries involving hepatitis B‑positive blood.

Adverse reactions to Hepetra are generally related to the immunoglobulin product and the intravenous route.

Common: - Fever or chills shortly after infusion. - Headache or mild dizziness. - Nausea, vomiting, or abdominal discomfort. - Localized pain, erythema, or swelling at the infusion site. - Transient increase in liver enzymes.

Serious: - Anaphylactic or severe allergic reactions, including urticaria, bronchospasm, or hypotension. - Acute hemolytic transfusion reaction. - Renal impairment or acute kidney injury. - Thrombotic events such as deep‑vein thrombosis or pulmonary embolism. - Severe aseptic meningitis.

Healthcare providers should evaluate several factors before prescribing Hepetra to ensure safe administration.

- Verify hepatitis B surface antigen status and prior immunization history of the patient. - Assess for known hypersensitivity to human immunoglobulins or any component of the formulation. - Monitor vital signs and for signs of allergic reaction during and after infusion. - Adjust dosing in patients with renal insufficiency or severe liver disease. - Use caution in pregnant or breastfeeding women; benefits should outweigh potential risks. - Ensure appropriate storage conditions and avoid using product beyond its expiration date.

Hepetra may interact with other agents, primarily affecting immune response or infusion safety.

Avoid: - Concurrent administration of other blood products or immunoglobulins without proper interval, which may increase risk of overload or adverse reactions. - Live vaccines administered within 4 weeks of Hepetra, as passive antibodies can diminish vaccine efficacy.

Use with caution: - Immunosuppressive drugs (e.g., corticosteroids, biologics) that may alter antibody clearance. - Anticoagulants, because infusion may affect coagulation parameters. - Renal‑toxic medications, given potential for renal impairment in rare adverse events. - Cytotoxic chemotherapy agents, due to combined immunosuppressive effects.